However little attention has been paid to targeting the MEK/MAPK pathway in HER2-positive breast cancer despite the fact that it is also frequently activated in this disease and has been recently established as a potential target for therapy [12]. This evidence concerns the gene MAP2K7 and breast carcinoma.